GANX Stock Gain Therapeutics, Inc.
US · NasdaqGMLast in our picks 2026-10-20 — not in the current list; analysis below is from that screen
Early-stage neurological pipeline offers extreme upside potential but carries substantial clinical risk.
Signal breakdown
- ▸Consensus Strong Buy with highly speculative multi-bagger target.
- ▾Below 50-day MA (-29.97%)
- ▾Near 52-week low (1.3% of range)
Is GANX a buy right now?
Trend: GANX is trading below the 50-day average (-26.32%), RSI 62 — neutral momentum, with a 3-month return of -32.26%.
Valuation & quality: Gain Therapeutics, Inc. trades on forward P/E -1.7, price-to-book 4.41; fundamentals show net margin 0.0%, return on equity -268.3%.
Analyst consensus: 5 analysts have a mean 12-month price target of $7.20 (+526.1% vs the last close; range $5.00 – $8.00), consensus rating “strong buy”.
Our screen: WATCH (score 0) — Early-stage neurological pipeline offers extreme upside potential but carries substantial clinical risk.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -25.70% | -2.60% | +3.20% | +4.10% | -17.20% | +7.10% | -3.90% | -27.20% |
Fundamentals
Analyst price target
Technical signals
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.
Sector: Healthcare · Industry: Biotechnology · United States · 20 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.